Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy

• Verfasst von: Chinot, Olivier L. [VerfasserIn]
• Verfasst von: Wick, Wolfgang [VerfasserIn]
• Titel: Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy
• Titelzusatz: an exploratory analysis of AVAglio
• Verf.angabe: Olivier L. Chinot, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Timothy Cloughesy, Josep Garcia, Cedric Revil, Lauren Abrey, and Wolfgang Wick
• Umfang: 6 S.
• Fussnoten: Gesehen am 07.02.2018
• Titel Quelle: Enthalten in: Neuro-Oncology
• Jahr Quelle: 2016
• Band/Heft Quelle: 18(2016), 9, S. 1313-1318
• ISSN Quelle: 1523-5866
• DOI: doi:10.1093/neuonc/now046
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1568516010

Abstract

BackgroundIn this post-hoc, exploratory analysis, we examined outcomes for patients enrolled in the AVAglio trial of front-line bevacizumab or placebo plus radiotherapy/temozolomide who received only a single line of therapy.MethodsPatients with newly diagnosed glioblastoma received protocol-defined treatment until progressive disease (PD). Co-primary endpoints were investigator-assessed progression-free survival (PFS) and overall survival (OS). After confirmed PD, patients were treated at the investigators' discretion. PFS/OS were assessed in patients with a PFS event who did not receive post-PD therapy (Group 1) and patients with a PFS event who received post-PD therapy plus patients who did not have a PFS event at the final data cutoff (Group 2). Kaplan-Meier methodology was used. A multivariate Cox proportional hazards model for known prognostic variables was generated.ResultsBaseline characteristics were balanced. In patients with a PFS event who did not receive post-PD therapy (Group 1; n = 225 [24.4% of the intent-to-treat population]), the addition of bevacizumab to radiotherapy/temozolomide resulted in a 3.6-month extension in both median PFS (hazard ratio [HR]: 0.62, P = .0016) and median OS (HR: 0.67, P = .0102). Multivariate analyses supported this OS benefit (HR: 0.66). In the remaining patients (Group 2; n = 696), a 5.2-month PFS extension was observed in bevacizumab-treated patients (HR: 0.61, P < .0001); OS was comparable between the treatment arms (HR: 0.88, P = .1502). No significant differences in safety were observed between the 2 groups.ConclusionThis exploratory analysis suggests that the addition of bevacizumab to standard glioblastoma treatment prolongs PFS and OS for patients with PD who receive only one line of therapy.